450 related articles for article (PubMed ID: 27528625)
1. Androgen receptor signaling pathways as a target for breast cancer treatment.
Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A
Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
3. Targeting the androgen receptor in breast cancer.
Chia K; O'Brien M; Brown M; Lim E
Curr Oncol Rep; 2015 Feb; 17(2):4. PubMed ID: 25665553
[TBL] [Abstract][Full Text] [Related]
4. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
5. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
6. Targeting the androgen receptor in triple-negative breast cancer.
Gucalp A; Traina TA
Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
[TBL] [Abstract][Full Text] [Related]
7. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
8. Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.
Christenson JL; Trepel JB; Ali HY; Lee S; Eisner JR; Baskin-Bey ES; Elias AD; Richer JK
Horm Cancer; 2018 Apr; 9(2):82-94. PubMed ID: 29340907
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
10. Consideration of breast cancer subtype in targeting the androgen receptor.
Venema CM; Bense RD; Steenbruggen TG; Nienhuis HH; Qiu SQ; van Kruchten M; Brown M; Tamimi RM; Hospers GAP; Schröder CP; Fehrmann RSN; de Vries EGE
Pharmacol Ther; 2019 Aug; 200():135-147. PubMed ID: 31077689
[TBL] [Abstract][Full Text] [Related]
11. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.
Kono M; Fujii T; Lim B; Karuturi MS; Tripathy D; Ueno NT
JAMA Oncol; 2017 Sep; 3(9):1266-1273. PubMed ID: 28301631
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Androgen Receptor Signaling in Breast Malignancies.
Christopoulos PF; Vlachogiannis NI; Vogkou CT; Koutsilieris M
Anticancer Res; 2017 Dec; 37(12):6533-6540. PubMed ID: 29187427
[TBL] [Abstract][Full Text] [Related]
13. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
[TBL] [Abstract][Full Text] [Related]
14. Ceritinib is a novel triple negative breast cancer therapeutic agent.
Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory.
Nahleh Z
Future Oncol; 2008 Feb; 4(1):15-21. PubMed ID: 18240997
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
[TBL] [Abstract][Full Text] [Related]
17. The Androgen Receptor: Is It a Promising Target?
Gucalp A; Traina TA
Ann Surg Oncol; 2017 Oct; 24(10):2876-2880. PubMed ID: 28766215
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer.
You CP; Leung MH; Tsang WC; Khoo US; Tsoi H
Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053220
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical signaling pathways of triple negative and triple positive breast cancers: What is new?
Elsers DA; Masoud EM; Kamel NAMH; Ahmed AM
Ann Diagn Pathol; 2021 Dec; 55():151831. PubMed ID: 34634762
[TBL] [Abstract][Full Text] [Related]
20. Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?
Sharifi MN; O'Regan RM; Wisinski KB
Clin Breast Cancer; 2023 Dec; 23(8):813-824. PubMed ID: 37419745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]